% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sachpekidis:143013,
      author       = {C. Sachpekidis$^*$ and A. Kopp-Schneider$^*$ and L.
                      Hakim-Meibodi and A. Dimitrakopoulou-Strauss$^*$ and J. C.
                      Hassel},
      title        = {18{F}-{FDG} {PET}/{CT} longitudinal studies in patients
                      with advanced metastatic melanoma for response evaluation of
                      combination treatment with vemurafenib and ipilimumab.},
      journal      = {Melanoma research},
      volume       = {29},
      number       = {2},
      issn         = {0960-8931},
      address      = {[s.l.]},
      publisher    = {Ovid},
      reportid     = {DKFZ-2019-00638},
      pages        = {178 - 186},
      year         = {2019},
      abstract     = {Sixteen BRAF-mutation positive, metastatic melanoma
                      patients with highly advanced disease received combination
                      therapy of vemurafenib and ipilimumab as an individual
                      treatment decision. Our aim was to assess the role of
                      fluorine-18-fluorodeoxyglucose (F-FDG) PET/computed
                      tomography (PET/CT) in the evaluation of the clinical
                      benefit (CB) of this combination treatment. After clinical
                      improvement under vemurafenib monotherapy, four cycles of
                      ipilimumab were additionally administered. F-FDG PET/CT was
                      performed before the start, after two cycles and after
                      completion of the combined ipilimumab/vemurafenib treatment.
                      PET-based patient response evaluation to treatment was based
                      on the European Organization for Research and Treatment of
                      Cancer and the PET Response Evaluation Criteria for
                      Immunotherapy criteria. Progression-free survival (PFS) from
                      the end of combination treatment was calculated. According
                      to their best clinical response at the end of combination
                      treatment, eight patients showed CB and eight patients had
                      no-CB. Two patients revealed extraordinary good clinical
                      outcome with PFS of more than 5 years. Overall, 13 out of 16
                      patients were correctly classified by the European
                      Organization for Research and Treatment of Cancer and 15 out
                      of 16 by the PET Response Evaluation Criteria for
                      Immunotherapy criteria. Median PFS was 8.8 months among
                      PET-responders and 3.6 months among nonresponders. During
                      immunotherapy administration seven patients developed
                      radiologic signs of immune-related adverse events (irAEs),
                      with colitis and arthritis being the most frequent ones;
                      these patients had a significantly longer PFS than those
                      without irAEs (P=0.036). F-FDG PET/CT is a valuable tool for
                      the evaluation of patients receiving a combination of
                      targeted treatment and immunotherapy. The appearance of
                      irAEs on PET/CT might correlate with benefit to
                      immunotherapy.},
      cin          = {E060 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)E060-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:30653029},
      doi          = {10.1097/CMR.0000000000000541},
      url          = {https://inrepo02.dkfz.de/record/143013},
}